IL37 and psoriasis: Finally, for patients affected by both psoriasis and IBD, first-line therapy is represented by TNF-alpha inhibitors, particularly adalimumab and infliximab, with second-line therapy involving certolizumab pegol, ustekinumab, and IL-23 inhibitors, with the strong recommendation to avoid IL-17 inhibitors [26].